The Journal of Clinical Psychiatry

Page 540

More JCP Articles

Academic Highlights

Reducing the Risk for Suicide in Schizophrenia and Affective Disorders.

September 15, 2003

Original Research

Suicidal Ideation and Attempts Among Psychiatric Patients With Major Depressive Disorder

September 15, 2003

T. Petteri Sokero , Tarja K. Melartin , Heikki J. Rytsälä , et al

Original Research

Suicide Attempts Among Veterans Seeking Treatment for Pathological Gambling

September 15, 2003

Otto Kausch

Original Research

Treatment of Previously Undiagnosed Psychiatric Disorders in Persons With Developmental Disabilities Decreased or Eliminated Self-Injurious Behavior

September 15, 2003

John A. Tsiouris , Ira L. Cohen , Paul J. Patti , et al

Letter to the Editor

Underdiagnosis of Bipolar II Disorders in the Community

September 15, 2003

Franco Benazzi

Letter to the Editor

Charles Bonnet Syndrome With Visual Hallucinations of Childhood Experience: Successful Treatment of 1 Patient With Risperidone

September 1, 2003

Kazuhisa Maeda , Yukihiko Shirayama , Shu Nukina , et al

Book Review

Infanticide: Psychosocial and Legal Perspectives on Mothers Who Kill

September 1, 2003

Book Review

Outcomes in Neurodevelopment and Genetic Disorders

September 1, 2003

Article

Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder (ADHD) Decreases the Risk for Substance Abuse: Findings From a Longitudinal Follow-Up of Youths With and Without ADHD

September 1, 2003

Joseph Biederman

Letter to the Editor

Polypharmacy in Schizophrenia: A Fuzzy Concept

September 1, 2003

Oliver Freudenreich , Donald C. Goff

Letter to the Editor

Reply to Polypharmacy in Schizophrenia: A Fuzzy Concept

September 1, 2003

Stephen M. Stahl

Letter to the Editor

Six-Month Review of Weight and Metabolic Parameters in Patients Receiving Clozapine, Risperidone, Olanzapine, or Quetiapine

September 1, 2003

Deanna L. Kelly , Julie Kreyenbuhl , Raymond C. Love , et al

« 1 … 538 539 540 541 542 … 755 »

Reducing the Risk for Suicide in Schizophrenia and Affective Disorders.

Suicidal Ideation and Attempts Among Psychiatric Patients With Major Depressive Disorder

Suicide Attempts Among Veterans Seeking Treatment for Pathological Gambling

Treatment of Previously Undiagnosed Psychiatric Disorders in Persons With Developmental Disabilities Decreased or Eliminated Self-Injurious Behavior

Underdiagnosis of Bipolar II Disorders in the Community

Charles Bonnet Syndrome With Visual Hallucinations of Childhood Experience: Successful Treatment of 1 Patient With Risperidone

Infanticide: Psychosocial and Legal Perspectives on Mothers Who Kill

Outcomes in Neurodevelopment and Genetic Disorders

Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder (ADHD) Decreases the Risk for Substance Abuse: Findings From a Longitudinal Follow-Up of Youths With and Without ADHD

Polypharmacy in Schizophrenia: A Fuzzy Concept

Reply to Polypharmacy in Schizophrenia: A Fuzzy Concept

Six-Month Review of Weight and Metabolic Parameters in Patients Receiving Clozapine, Risperidone, Olanzapine, or Quetiapine

ELSEWHERE:

FOLLOW US:

More JCP Articles

Reducing the Risk for Suicide in Schizophrenia and Affective Disorders.

Suicidal Ideation and Attempts Among Psychiatric Patients With Major Depressive Disorder

Suicide Attempts Among Veterans Seeking Treatment for Pathological Gambling

Treatment of Previously Undiagnosed Psychiatric Disorders in Persons With Developmental Disabilities Decreased or Eliminated Self-Injurious Behavior

Underdiagnosis of Bipolar II Disorders in the Community

Charles Bonnet Syndrome With Visual Hallucinations of Childhood Experience: Successful Treatment of 1 Patient With Risperidone

Infanticide: Psychosocial and Legal Perspectives on Mothers Who Kill

Outcomes in Neurodevelopment and Genetic Disorders

Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder (ADHD) Decreases the Risk for Substance Abuse: Findings From a Longitudinal Follow-Up of Youths With and Without ADHD

Polypharmacy in Schizophrenia: A Fuzzy Concept

Reply to Polypharmacy in Schizophrenia: A Fuzzy Concept

Six-Month Review of Weight and Metabolic Parameters in Patients Receiving Clozapine, Risperidone, Olanzapine, or Quetiapine

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles